Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ethionamide

FDA-approved product (tablet, oral), marketed as Trecator.

Registered studies
16
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ethionamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiocarbamide derivatives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AD03

Repurposing investigation

Ethionamide is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae6.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

16registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Ethionamide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ethionamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis

    NCT07350174 · start 2026-03-30

    Registered record
    Registry ID
    NCT07350174
    Conditions
    Tuberculosis Meningitis
    Interventions
    HRZE; HRZE plus Alpe375; HRZE plus AlpE500; HRZE plus AlpE625
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03-30
    Completion
    2028-10-30
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Meningitis
    InterventionHRZE; HRZE plus Alpe375; HRZE plus AlpE500; HRZE plus AlpE625
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

    NCT06748937 · start 2025-03-03

    Registered record
    Registry ID
    NCT06748937
    Conditions
    Tuberculosis
    Interventions
    Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-03
    Completion
    2026-03-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionAlpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    PhasePhase 2
    Registry statusRecruiting

  • PanACEA - STEP2C -01

    NCT05807399 · start 2023-04-14

    Registered record
    Registry ID
    NCT05807399
    Conditions
    Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
    Interventions
    BTZ-043; Rifampicin; Isoniazid; Pyrazinamide; Moxifloxacin; Alpibectir (GSK3729098); Ganfeborole (GSK3036656); Delpazolid (LCB01-0371); Pretomanid (Pa); Ethambutol (E); Ethionamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-14
    Completion
    2027-12-30
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
    InterventionBTZ-043; Rifampicin; Isoniazid; Pyrazinamide +7 more
    PhasePhase 2
    Registry statusRecruiting

  • A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

    NCT05473195 · start 2022-12-06

    Registered record
    Registry ID
    NCT05473195
    Conditions
    Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
    Interventions
    BVL-GSK098 9mg; Ethionamide 250mg; Ethionamide 250 mg; Isoniazid 300 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-12-06
    Completion
    2024-04-16
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
    InterventionBVL-GSK098 9mg; Ethionamide 250mg; Ethionamide 250 mg; Isoniazid 300 MG
    PhasePhase 2
    Registry statusCompleted

  • The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia

    NCT05315661 · start 2022-07-06

    Registered record
    Registry ID
    NCT05315661
    Conditions
    Frontotemporal Dementia
    Interventions
    ET-STEM
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-07-06
    Completion
    2026-12-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFrontotemporal Dementia
    InterventionET-STEM
    PhasePhase 1
    Registry statusActive not recruiting

  • Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.

    NCT05258877 · start 2022-06-10

    Registered record
    Registry ID
    NCT05258877
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Plasma samples
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-10
    Completion
    2023-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionPlasma samples
    PhaseNot recorded
    Registry statusCompleted

  • Triage Test for All Oral DR-TB Regimen (TRiAD Study)

    NCT05175794 · start 2022-05-26

    Registered record
    Registry ID
    NCT05175794
    Conditions
    Drug Resistant Tuberculosis; MDR-TB; XDR-TB; Tuberculosis
    Interventions
    Xpert® MTB/XDR
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-05-26
    Completion
    2025-06-01
    Enrolment
    786

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Resistant Tuberculosis; MDR-TB; XDR-TB; Tuberculosis
    InterventionXpert® MTB/XDR
    PhaseNot recorded
    Registry statusCompleted

  • TB-CAPT MTB/XDR Study

    NCT04567368 · start 2021-05-14

    Registered record
    Registry ID
    NCT04567368
    Conditions
    Tuberculosis; Resistance Bacterial; Diagnoses Disease
    Interventions
    Xpert MTB/XDR
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-05-14
    Completion
    2024-12-30
    Enrolment
    753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Resistance Bacterial; Diagnoses Disease
    InterventionXpert MTB/XDR
    PhaseNot recorded
    Registry statusActive not recruiting

  • Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

    NCT03625739 · start 2018-07-01

    Registered record
    Registry ID
    NCT03625739
    Conditions
    Tuberculosis
    Interventions
    anti-tuberculosis drug
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-07-01
    Completion
    2026-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionanti-tuberculosis drug
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin

    NCT02975570 · start 2017-08

    Registered record
    Registry ID
    NCT02975570
    Conditions
    Tuberculosis Multi Drug Resistant Active
    Interventions
    Delamanid; Linezolid; Levofloxacin; Pyrazinamide; WHO MDR-TB regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2017-08
    Completion
    2022-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Multi Drug Resistant Active
    InterventionDelamanid; Linezolid; Levofloxacin; Pyrazinamide +1 more
    PhasePhase 3
    Registry statusWithdrawn

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

    NCT02454205 · start 2015-11-12

    Registered record
    Registry ID
    NCT02454205
    Conditions
    Tuberculosis; Multidrug Resistant Tuberculosis; Extensively-drug Resistant Tuberculosis
    Interventions
    Linezolid; Bedaquiline; Levofloxacin; Pyrazinamide; Isoniazid; Ethionamide; Terizidone; Moxifloxacin; Kanamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-11-12
    Completion
    2021-08-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Tuberculosis; Extensively-drug Resistant Tuberculosis
    InterventionLinezolid; Bedaquiline; Levofloxacin; Pyrazinamide +5 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

    NCT02365623 · start 2015-02-18

    Registered record
    Registry ID
    NCT02365623
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    TMC207 (bedaquiline); Background Regimen (BR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-18
    Completion
    2018-11-08
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionTMC207 (bedaquiline); Background Regimen (BR)
    PhasePhase 2
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted